Skip to main content
SpringerLink
Log in

Switching TNFa inhibitor incurs higher costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, US.

Reference

  • Dalen J, et al. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-alpha Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study. Advances in Therapy : 9 Jul 2020. Available from: URL: http://doi.org/10.1007/s12325-020-01425-8

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Switching TNFa inhibitor incurs higher costs. PharmacoEcon Outcomes News 858, 29 (2020). https://doi.org/10.1007/s40274-020-7002-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7002-3

Search

Navigation